Embecta (EMBC) Competitors $13.78 -0.41 (-2.89%) Closing price 04:00 PM EasternExtended Trading$13.78 0.00 (0.00%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. LIVN, WRBY, INSP, EYE, PRCT, AORT, LMAT, LQDA, ENOV, and CDREShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), National Vision (EYE), PROCEPT BioRobotics (PRCT), Artivion (AORT), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), Enovis (ENOV), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors LivaNova Warby Parker Inspire Medical Systems National Vision PROCEPT BioRobotics Artivion LeMaitre Vascular Liquidia Technologies Enovis Cadre LivaNova (NASDAQ:LIVN) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Which has more volatility & risk, LIVN or EMBC? LivaNova has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Do analysts rate LIVN or EMBC? LivaNova presently has a consensus target price of $59.71, suggesting a potential upside of 14.50%. Embecta has a consensus target price of $19.00, suggesting a potential upside of 37.88%. Given Embecta's stronger consensus rating and higher possible upside, analysts clearly believe Embecta is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Embecta 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 Does the media prefer LIVN or EMBC? In the previous week, LivaNova had 9 more articles in the media than Embecta. MarketBeat recorded 10 mentions for LivaNova and 1 mentions for Embecta. Embecta's average media sentiment score of 1.28 beat LivaNova's score of 0.24 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, LIVN or EMBC? Embecta has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.25B2.27$63.23M-$3.89-13.41Embecta$1.12B0.72$78.30M$1.439.64 Is LIVN or EMBC more profitable? Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-16.13% 14.57% 6.91% Embecta 7.58%-23.40%14.46% Do insiders & institutionals hold more shares of LIVN or EMBC? 97.6% of LivaNova shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 0.4% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryEmbecta beats LivaNova on 11 of the 17 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$829.90M$8.18B$6.12B$10.65BDividend Yield4.23%2.81%5.69%4.74%P/E Ratio9.6473.0985.6126.85Price / Sales0.7239.72612.81135.13Price / Cash4.2523.2237.7861.77Price / Book-1.086.8913.256.70Net Income$78.30M$247.60M$3.30B$276.44M7 Day Performance-2.34%1.67%4.70%3.13%1 Month Performance-7.89%1.69%8.43%10.21%1 Year Performance4.16%11.12%88.01%40.35% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.8144 of 5 stars$13.78-2.9%$19.00+37.9%+5.0%$829.90M$1.12B9.642,100Positive NewsLIVNLivaNova2.4878 of 5 stars$52.33-2.1%$59.71+14.1%-2.2%$2.92B$1.25B-13.452,900News CoverageWRBYWarby Parker1.7299 of 5 stars$27.69+0.3%$24.06-13.1%+57.8%$2.90B$771.32M-395.513,780News CoveragePositive NewsAnalyst ForecastINSPInspire Medical Systems4.8161 of 5 stars$75.46-2.3%$154.43+104.6%-64.5%$2.28B$802.80M43.621,246Analyst ForecastEYENational Vision2.2989 of 5 stars$29.24+2.5%$24.73-15.4%+166.3%$2.26B$1.82B-162.4413,411Positive NewsPRCTPROCEPT BioRobotics3.3588 of 5 stars$36.49-0.5%$70.00+91.8%-51.5%$2.04B$274.95M-23.54430AORTArtivion3.0862 of 5 stars$42.03+2.4%$43.13+2.6%+54.3%$1.94B$388.54M-100.061,600LMATLeMaitre Vascular3.9423 of 5 stars$85.45+1.5%$97.60+14.2%-4.5%$1.91B$219.86M41.48490News CoverageLQDALiquidia Technologies3.4332 of 5 stars$22.80+4.6%$32.11+40.8%+127.9%$1.88B$14M-13.4150News CoverageAnalyst ForecastENOVEnovis3.7876 of 5 stars$30.19+0.7%$51.00+68.9%-23.1%$1.71B$2.11B-2.127,367Positive NewsCDRECadre2.2029 of 5 stars$36.06-0.8%$31.50-12.6%-3.8%$1.48B$567.56M38.362,284 Related Companies and Tools Related Companies LIVN Alternatives WRBY Alternatives INSP Alternatives EYE Alternatives PRCT Alternatives AORT Alternatives LMAT Alternatives LQDA Alternatives ENOV Alternatives CDRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
